Pharma and biotech bigwigs always look to bolster their product portfolios and pipelines through collaborations and buyouts. While oncology and immuno-oncology companies have always been ...

In 2006, total biotech financing reached $48.3 billion. That's $3 billion more than biotech companies raised in 2000 (Fig. 2). But last year, the main sources of financing were wholly different ...

Tilt your stock portfolio toward biotech companies now and you could stand to make substantial profits in the near future. You can also find cost-effective stocks under $20 to trade daily on the ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Biotech stocks are companies that use living organisms to make drugs and vaccines. Often, they merge cutting-edge technology with new findings in molecular science and virology to treat life ...

If these times have anything to say about it, the next Microsoft is coming from the biotech sector. Investors are moving in looking for profits, even putting companies without products on the map.

Companies facing steep revenue losses will be seeking to refill their pipelines, creating a ripe environment for “the biotech innovation engine” as noted in a market report authored by Dr.

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation created a window of reprieve for the affected biotech companies.